Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4132122 | 0.90 | TLR7 (0.60) | TLR7 | |
| SCHEMBL2589596 | 0.87 | TLR7 (0.77) | TLR7IL6 | |
| SCHEMBL4633208 | 0.87 | TLR7 (0.53) | TLR7 | |
| SCHEMBL13798674 | 0.87 | TLR7 (0.71) | TLR7 | |
| SCHEMBL2862789 | 0.87 | TLR7 (0.60) | TLR7 | |
| SCHEMBL3280954 | 0.86 | TLR7 (0.61) | TLR7IL6 | |
| SCHEMBL1146322 | 0.85 | TLR7 (0.79) | TLR7IL6 | |
| SCHEMBL1244619 | 0.85 | TLR7 (0.62) | TLR7 | |
| SCHEMBL1344514 | 0.84 | TLR7 (0.66) | TLR7IL6 | |
| SCHEMBL9935626 | 0.84 | TLR7 (0.59) | TLR7IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121693-B1 | 8-OXOADENINE DERIVATIVES AS IMMUNO-MODULATORS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | claimed |
| US-8067411-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-11-29 | — | — | US | claimed |
| US-20080300244-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | claimed |
| EP-2121693-B1 | 8-OXOADENINE DERIVATIVES AS IMMUNO-MODULATORS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-8067411-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-11-29 | — | — | US | disclosed |
| US-8067411-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-11-29 | — | — | US | disclosed |
| US-8067411-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-11-29 | — | — | US | disclosed |
| EP-2121693-A1 | 8-OXOADENINE DERIVATIVES AS IMMUNO-MODULATORS | AstraZeneca AB (SE) | 2009-11-25 | — | — | EP | disclosed |
| US-20080300244-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| US-20080300244-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| US-20080300244-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| WO-2008071976-A1 | 8-OXOADENINE DERIVATIVES AS IMMUNO-MODULATORS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300244-A1 | NOVEL COMPOUNDS | NPY1R, F12, NPY2R | TLR7 3711/4885IL6 4407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.